Lab test could predict which cystic fibrosis patients benefit from drug
NCT ID NCT03894657
Summary
This study aimed to see if a laboratory test on patients' own nasal cells could predict how well they would respond to the cystic fibrosis drug Orkambi. Researchers tested 91 patients with a specific genetic form of cystic fibrosis who were starting Orkambi treatment. They compared results from the nasal cell test to actual improvements in patients' lung function over 24-48 weeks of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Necker-Enfants Malades
Paris, Île-de-France Region, 75015, France
Conditions
Explore the condition pages connected to this study.